Statins and New-Onset Diabetes

Author(s): Marcin Barylski, Dragana Nikolic, Maciej Banach, Peter P. Toth, Giuseppe Montalto, Manfredi Rizzo

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 22 , 2014

Become EABM
Become Reviewer
Call for Editor


Statins are highly efficacious lipid modifying agents that reduce the risk for cardiovascular (CV) events in both primary and secondary prevention settings. However, statins affect molecular mechanisms which adversely impact on insulin sensitivity and β-cell function, thereby increasing risk for new onset diabetes mellitus (NOD). Defining the mechanisms involved is the focus of considerable current investigation. The statins reduce the risk for CV events in normoglycemic patients as well as in those with diabetes mellitus (DM) and their benefits outweigh the risk of inducing NOD. We review the clinical evidence for NOD with statin treatment, as well as the potential mechanisms involved. Our literature search was based on PubMed and Scopus listings. Further large studies are needed to elucidate both the association between NOD and statin use and the underlying mechanisms.

Keywords: New-onset diabetes mellitus, statin, cardiovascular events, insulin sensitivity, primary prevention, secondary prevention.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 08 June, 2014
Page: [3657 - 3664]
Pages: 8
DOI: 10.2174/13816128113196660678
Price: $65

Article Metrics

PDF: 28